Theraclion Initiates Its Commercial Momentum in the First Half of 2026
Regulatory News:
THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), today reports on its progress during the first half of 2026.
By the end of the first half of 2026, Theraclion's commercial acceleration is beginning to show clearly across every stage of the sales cycle. This momentum has been accompanied by significant progress across all the company's strategic development areas:
Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the installed base, particularly across Europe.
